Key terms

About SAGE

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest SAGE news

Yesterday 4:55am ET Sage Therapeutics management to meet with Piper Sandler Mar 27 9:50pm ET Analysts Are Neutral on These Healthcare Stocks: SAGE Therapeutics (SAGE), Adverum Biotechnologies (ADVM) Mar 26 8:42am ET SAGE Therapeutics Board Member Announces Retirement Mar 26 6:12am ET Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics, Inc. (APGE), SAGE Therapeutics (SAGE) Mar 11 6:50am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Janux Therapeutics Inc (JANX) and SAGE Therapeutics (SAGE) Feb 23 11:55am ET JPMorgan biotech analysts to hold an analyst/industry conference call Feb 23 11:00am ET JPMorgan biotech analysts to hold an analyst/industry conference call Feb 19 12:51am ET Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), SAGE Therapeutics (SAGE) and IQVIA Holdings (IQV) Feb 16 11:22am ET Biotech Alert: Searches spiking for these stocks today Feb 16 8:30am ET Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE) and EyePoint Pharmaceuticals (EYPT) Feb 15 10:05am ET SAGE Therapeutics’ Zurzuvae Launch: A Promising Start Amid Operational Cautions Feb 15 10:01am ET Sage Therapeutics price target raised to $28 from $25 at H.C. Wainwright Feb 15 8:56am ET Sage Therapeutics price target raised to $26 from $21 at RBC Capital Feb 15 8:38am ET Sage Therapeutics price target raised to $25 from $23 at Oppenheimer Feb 15 8:03am ET Analysts Conflicted on These Healthcare Names: Genmab (GMAB), cbdMD (YCBD) and SAGE Therapeutics (SAGE) Feb 15 7:20am ET Analysts Offer Insights on Healthcare Companies: CSL (OtherCMXHF), SAGE Therapeutics (SAGE) and Illumina (ILMN) Feb 15 7:02am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Stryker (SYK), SAGE Therapeutics (SAGE) and Healthcare Services (HCSG) Feb 15 6:11am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Tenet Healthcare (THC), SAGE Therapeutics (SAGE) and American Well (AMWL) Feb 15 1:02am ET Bad News for SAGE Therapeutics, Inc. (US) Stock: This New Risk Has Been Added Feb 14 7:25pm ET Buy Rating for SAGE Therapeutics Amid Strong Early Demand for Zurzuvae and Solid Financial Position Feb 14 5:53pm ET Sage Therapeutics price target raised to $28 from $27 at Goldman Sachs Feb 14 6:33am ET Sage Therapeutics expects cash available will support its operations into 2026 Feb 14 6:32am ET Sage Therapeutics reports Q4 EPS (55c), consensus ($1.28) Feb 13 4:31pm ET Analysts Offer Insights on Healthcare Companies: Incyte (INCY), SAGE Therapeutics (SAGE) and Rocket Pharmaceuticals (RCKT) Feb 09 10:46am ET SAGE Therapeutics: Hold Rating with Modest Zurzuvae Sales and Shifted Focus to PPD-Only Investment Thesis Feb 09 10:38am ET Sage Therapeutics price target lowered to $25 from $27 at H.C. Wainwright Jan 25 4:24am ET SAGE Therapeutics Secures New Cambridge Headquarters Lease Jan 22 7:29am ET Sage Therapeutics price target raised to $22 from $20 at Truist Jan 19 7:16am ET Sage Therapeutics price target raised to $34 from $24 at Scotiabank Jan 17 7:52am ET Sage Therapeutics price target raised to $30 from $26 at BofA Jan 11 8:01am ET Analysts Offer Insights on Healthcare Companies: DocGo (DCGO), SAGE Therapeutics (SAGE) and Globus Medical (GMED)

No recent news articles are available for SAGE

No recent press releases are available for SAGE

SAGE Financials

1-year income & revenue

Key terms

SAGE Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

SAGE Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms